GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Diplomat Pharmacy Inc (NYSE:DPLO) » Definitions » Growth Rank

Diplomat Pharmacy (Diplomat Pharmacy) Growth Rank : 0 (As of May. 05, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Diplomat Pharmacy Growth Rank?

Diplomat Pharmacy has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.


Diplomat Pharmacy Growth Rank Related Terms

Thank you for viewing the detailed overview of Diplomat Pharmacy's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Diplomat Pharmacy (Diplomat Pharmacy) Business Description

Traded in Other Exchanges
N/A
Address
4100 South Saginaw Street, Flint, MI, USA, 48507
Diplomat Pharmacy Inc. is active in the U.S. healthcare sector. It provides specialty pharmacy and infusion services, including pharmacy solutions for chronic diseases. The company has two main segments: specialty pharmacy and pharmacy benefit management. Its specialty pharmacy segment offers solutions to dispense, deliver, and dose prescription drugs. The pharmacy benefit management segment offers services to help control pharmacy benefit dollars and maximize quality of care. It derives most of its revenue through prescription drug sales in the United States.
Executives
Brian T Griffin director, officer: Chairman and CEO
David C Dreyer director C/O SICOR INC, 19 HUGHES, IRVINE CA 92618-1902
Shawn Tomasello director C/O PHARMACYCLICS, INC, 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Regina M. Benjamin director 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Benjamin Wolin director C/O EVERYDAY HEALTH, INC., 345 HUDSON STREET, 16TH FLOOR, NEW YORK NY 10014
Jeffrey G Park director C/O DIPLOMAT PHARMACY, INC., 4100 S. SAGINAW ST., FLINT MI 48507
Sean Whelan director, officer: Chief Financial Officer C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48108
Jeffrey M Rowe director, officer: EVP of Operations C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018